Related Experiment Video
Updated: Jan 20, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
HPV-driven transcriptome and splicing rewiring under SRPK1 inhibition in cervical cancer
Afra Basera1,2, Mohammed Alaouna1, Janie Duvenhage3,4
1SAMRC Precision Oncology Research Unit (PORU), DSTI/NRF SARChI Chair in Precision Oncology and Cancer Prevention, Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield, Pretoria, South Africa.
Background:
Serine/arginine protein kinase 1 phosphorylates serine-arginine-rich (SR) proteins to regulate splice-site selection during alternative splicing. While its role in general RNA regulation is established, its contribution to the HPV-dependent transcriptome and splicing stratification in cervical cancer remains unclear. Therefore, we sought to determine how SRPK1 inhibition differentially remodels gene expression and alternative splicing in HPV+ versus HPV- cervical cancer cells.
Methods:
HPV16+ SiHa and HPV- C33A cervical cancer cells were treated with the SRPK1 inhibitor, SPHINX31. RNA profiling was performed, and differentially expressed genes were defined as |log2FC| ≥ 1.5. AS events were classified by SUPPA as exon skipping (SE), intron retention (RI), mutually exclusive exons (MXE), alternative 3' splice site (A3SS), and alternative 5' splice site (A5SS). Pathway enrichment was assessed using Gene Ontology/KEGG, STRING protein-protein interaction (PPI) networks, and Molecular Complex Detection (MCODE) was used to identify protein hubs. To determine computational prediction of docking, SPHINX31 was docked into SRPK1 (PDB 5MY8) using SP/XP docking and MM-GBSA rescoring.
Results:
SRPK1 inhibition was associated with distinct responses that were HPV-related. In C33A cells, upregulated genes were enriched for translation, RNA processing, and glycosylation, with KEGG highlighting ribosome and metabolic modules. Ribosomal hubs dominated the PPI/MCODE, suggesting possible translational and metabolic adjustments. In contrast, SiHa cells exhibited transcriptomic changes consistent with reduced expression of genes linked to Hippo, Wnt, PI3K-AKT, ERK1/2 signaling, migration, angiogenesis, and growth factor cytokine networks. Targets of YAP/TAZ (e.g., CCND1, BIRC5, SNAI2, SERPINE1) and their regulators (RASSF1, CSNK1E) were suppressed. At the splicing level, SiHa cells displayed fewer total AS events but with larger effect sizes, particularly in A3SS/A5SS. C33A cells showed abundant SE (59,234 events; small median ΔPSI) and RI (1,770 events, often binary), including complete shifts in HLA-DRB1/PLIN2 (+1.00) and KLF4 (-1.00). Notable A5SS switches included LEF1 (+1.00) and CDK6 (-1.00) in C33A, and DLX1/MRPL14/THAP5 (-1.00) in SiHa. Docking computationally predicted the low-energy poses of SPHINX31 in the SRPK1 ATP pocket. While not definitive, this evidence may potentially support the transcriptomic and splicing findings.
Conclusion:
SRPK1 inhibition may remodel the cervical cancer transcriptome in an HPV-linked manner, with SiHa cells exhibiting changes consistent with suppression of oncogenic signaling, whereas C33A cells adapt through translational and metabolic reprogramming.
Insights
Serine/arginine protein kinase 1 (SRPK1) inhibition differentially affects gene expression and alternative splicing in HPV-positive versus HPV-negative cervical cancer cells. HPV-positive cells show suppressed oncogenic signaling, while HPV-negative cells undergo metabolic reprogramming.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Splicing
Background:
- Serine/arginine protein kinase 1 (SRPK1) regulates alternative splicing by phosphorylating serine-arginine-rich (SR) proteins.
- The role of SRPK1 in HPV-dependent transcriptomes and splicing in cervical cancer is not fully understood.
- Investigating SRPK1's impact on gene expression and splicing in HPV-positive and HPV-negative cervical cancer cells is crucial.
Purpose of the Study:
- To determine how SRPK1 inhibition differentially remodels gene expression and alternative splicing in HPV-positive versus HPV-negative cervical cancer cells.
- To elucidate the distinct transcriptomic and splicing alterations induced by SRPK1 inhibition in different HPV contexts.
- To explore potential therapeutic strategies targeting SRPK1 in cervical cancer.
Main Methods:
- Treatment of HPV16-positive SiHa and HPV-negative C33A cervical cancer cells with the SRPK1 inhibitor SPHINX31.
- RNA profiling to identify differentially expressed genes and alternative splicing (AS) events (exon skipping, intron retention, etc.).
- Bioinformatic analyses including pathway enrichment (Gene Ontology/KEGG), protein-protein interaction networks (STRING/MCODE), and molecular docking (SP/XP, MM-GBSA).
Main Results:
- SRPK1 inhibition induced distinct, HPV-related responses. HPV-negative C33A cells showed enrichment for translation, RNA processing, and metabolic pathways, with ribosomal hubs dominating.
- HPV-positive SiHa cells exhibited reduced expression of genes in Hippo, Wnt, PI3K-AKT, and ERK1/2 signaling pathways, suppressing YAP/TAZ targets.
- SiHa cells had fewer AS events but larger effect sizes (A3SS/A5SS), while C33A cells showed abundant exon skipping and intron retention, with notable splicing switches in specific genes.
Conclusions:
- SRPK1 inhibition remodels the cervical cancer transcriptome in an HPV-dependent manner.
- HPV-positive cells show suppressed oncogenic signaling, whereas HPV-negative cells adapt via translational and metabolic reprogramming.
- These findings suggest distinct therapeutic vulnerabilities and adaptation mechanisms based on HPV status in cervical cancer.
Related Concept Videos
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
04:20Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
11:48Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

